卡培他滨单药或联合西妥昔单抗治疗老年晚期大肠癌临床研究

发布时间：2017-12-27 06:28

本文关键词：卡培他滨单药或联合西妥昔单抗治疗老年晚期大肠癌临床研究　出处：《苏州大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的观察和评价卡培他滨联合西妥昔单抗或卡培他滨单药治疗老年晚期大肠癌患者的疗效及毒副反应。方法回顾性分析36例老年晚期大肠癌患者生存资料(2011年7月至2014年12月我院经病理确诊),其中联合用药组18例:西妥昔单抗500mg/m2,d0;卡培他滨1000mg/m2 dl~d14;21d为1个周期。单药组18例:卡培他滨1000mg/m2 dl~d14;21d为1个周期。每例接受至少4周期化疗后评价疗效。结果两组36例均可评价,联合治疗组18例:有效率(CR+PR)为38.9%(7/18),SD为44.4%(8/18),PD为16.7%(3/18)。中位疾病进展时间(TTP)8.3个月,中位生存期(OS)17个月。单药组18例:有效率(CR+PR)为33.3%(6/18),SD为50%(9/18),PD为16.7%(3/18)。中位疾病进展时间(TTP)为5.1个月,中位生存期(OS)为16个月。两组间TTP比较,联合治疗组显著高于单药组,差异有统计学意义(P0.05),OS相比较,差异无统计学意义(P=0.65)。治疗相关毒副反应主要为手足综合症、皮疹及中性粒细胞减少,两组相比较,联合治疗组的皮疹发生率显著低于单药组,差异有统计学意义(P0.05)。结论卡培他滨联合西妥昔单抗方案显著提高老年晚期大肠癌的无进展生存时间,可使老年患者临床获益,其毒副反应可以耐受。
[Abstract]:Objective To observe and evaluate the efficacy and side effects of capecitabine combined with cetuximab or capecitabine in the treatment of elderly patients with advanced colorectal cancer. Methods the data of 36 elderly patients with advanced colorectal cancer were retrospectively analyzed. From July 2011 to December 2014, our hospital was confirmed by pathology. Among them, there were 18 cases in the combined medication group: Cetuximab 500mg/m2, d0, capecitabine 1000mg/m2 dl~d14 and 21d for 1 cycles. 18 cases of single drug group: capecitabine 1000mg/m2 dl~d14; 21d for 1 cycles. Each case received at least 4 cycles of chemotherapy to evaluate the efficacy. Results there were 36 cases in two groups and 18 cases in the combined treatment group: the effective (CR+PR) was 38.9% (7/18), SD was 44.4% (8/18), and PD was 16.7% (3/18). The median disease progression time (TTP) was 8.3 months, and the median survival time (OS) was 17 months. In 18 cases of single drug group, the effective rate (CR+PR) was 33.3% (6/18), SD was 50% (9/18), and PD was 16.7% (3/18). The median disease progression time (TTP) was 5.1 months and the median survival time (OS) was 16 months. TTP comparison between the two groups, the combined treatment group was significantly higher than the single drug group, the difference was statistically significant (P0.05), OS phase comparison, the difference was not statistically significant (P=0.65). The main side effects were hand foot syndrome, rash and neutrophils. Compared with the two groups, the incidence of rash in the combined treatment group was significantly lower than that in the single drug group (P0.05). Conclusion the combination of capecitabine and cetuximab can significantly improve the progression free survival time of elderly patients with advanced colorectal cancer, which can benefit the elderly patients, and the side effects can be tolerated.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R735.34

【相似文献】